Compare PCRX & ARI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | ARI |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 884.4M |
| IPO Year | 2010 | 2009 |
| Metric | PCRX | ARI |
|---|---|---|
| Price | $24.70 | $6.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $30.00 | $8.00 |
| AVG Volume (30 Days) | 468.1K | ★ 2.6M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 16.05% |
| EPS Growth | 107.44 | ★ 183.51 |
| EPS | 0.19 | ★ 0.27 |
| Revenue | ★ $541,533,000.00 | $271,589,000.00 |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.69 | N/A |
| P/E Ratio | $132.47 | ★ $23.07 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $6.11 |
| 52 Week High | $27.66 | $11.24 |
| Indicator | PCRX | ARI |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 30.61 |
| Support Level | $24.61 | N/A |
| Resistance Level | $25.17 | $7.00 |
| Average True Range (ATR) | 0.77 | 0.11 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 42.46 | 30.79 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.